New pathway: Vemurafenib Pathway, Pharmacodynamics

We have added a new pathway: Vemurafenib PD pathway to our pathway collections.

Vemurafenib (marketed as ZELBORAF) is an oral BRAF inhibitor used to treat late-stage melanoma.  It specifically targets the mutant BRAF protein (V600E isoform) that is found in approximately half of all cases of melanoma. Vemurafenib is a personalized targeted therapy and it is only designed to be used in patients with the BRAF V600E mutation, but not for use in patients with wild-type BRAF melanoma.

PharmGKB Vemurafenib PD pathway describes the mechanism of action of vemurafenib and how it blocks tumor cell proliferation and survival via targeting BRAF V600E to effectively inhibit the MAPK signaling pathway.  

View or download the pathway at Vemurafenib PD pathway.

View all pathways at PharmGKB.

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.